Published :
Tables : 54
Figures : 46
Category : Healthcare
No. of Pages : 235
Report Code : HC-U4618
Dermatology Drugs Market Overview: FutureWise Market Research has instantiated a report that provides an intricate analysis of Dermatology Drugs Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Dermatology Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Dermatology Drugs Market: • Novartis AG • Bristol-Myers Squibb Company • Johnson & Johnson • Merck & Co. Inc. • Amgen Inc. • AbbVie Inc. • Eli Lilly and Company • Galderma S.A. • GlaxoSmithKline plc • Mylan N.V. • LEO Pharma A/S. • Sanofi • Ortho-Clinical • Helena Laboratories • Sklar Surgical Instruments (Note: The list of the major players will be updated with the latest market scenario and trends) Dermatology Drugs Market Segmentation: By Treatment Type • Topical corticosteroids • Lower Limb Prosthetic • Biologics • Calcimeurin Inhibitors • Antihistamines • Hormone Therapy • Others By Drug Type • Humira • Remicade • Otezla • Stelara • Enbrel • Cosentyx • Neoral • Taltz • Cubicin • Canesten • Zyvox • Dupixent • Protopic • Valtrex • Eucrisa • Others By Prescription Mode • Prescription drugs • OTC drugs By Therapeutic Area • Psoriasis • Atopic dermatitis • Acne By Distribution Channel • Direct • Wholesale/retail • Online By End User • Hospital • Cosmetic Centers • Clinics By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Dermatology Drugs Market By Treatment Type, By Drug Type, By Prescription Mode, By Therapeutic Area, By Distribution Channel, By End User and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexibility Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customisation offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Dermatology Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Dermatology Drugs Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Dermatology Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Dermatology Drugs Market, By Treatment Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Topical corticosteroids 7.2. Retinoids 7.3. Biologics 7.4. Calcineurin Inhibitors 7.5. Antihistamines 7.6. Hormone Therapy 7.7. Others 8. Dermatology Drugs Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Humira 8.2. Remicade 8.3. Otezla 8.4. Stelara 8.5. Enbrel 8.6. Cosentyx 8.7. Neoral 8.8. Taltz 8.9. Cubicin 8.10.Canesten 8.11.Zyvox 8.12.Dupixent 8.13.Protopic 8.14.Valtrex 8.15.Eucrisa 8.16.Others 9. Dermatology Drugs Market, By Prescription Mode Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Prescription drugs 9.2. OTC drugs 10. Dermatology Drugs Market, By Therapeutic Area Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Psoriasis 10.2. Atopic dermatitis 10.3. Acne 10.4. Rosacea 10.5. Skin Cancer 10.6. Scar 10.7. Others 11. Dermatology Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Direct 11.2. Wholesale/retail 11.3. Online 12. Dermatology Drugs Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 12.1. Hospital 12.2. Cosmetic Centers 12.3. Clinics 13. North America Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. U.S.A 13.2.2. Canada 13.2.3. Mexico 13.3. Market Size (USD Million) Forecast for North America 2022-2028 14. Latin America Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Brazil 14.2.2. Venezuela 14.2.3. Argentina 14.2.4. Rest of Latin America 14.3. Market Size (USD Million) Forecast for Latin America 2022-2028 15. Europe Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Germany 15.2.2. U.K 15.2.3. France 15.2.4. Italy 15.2.5. Spain 15.2.6. Russia 15.2.7. Poland 15.2.8. Rest of Europe 15.3. Market Size (USD Million) Forecast for Europe 2022-2028 16. Asia Pacific Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. Japan 16.2.2. China 16.2.3. India 16.2.4. Australia and New Zealand 16.2.5. ASEAN 16.2.6. Rest of Asia Pacific 16.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 17. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 17.1. Introduction 17.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 17.2.1. GCC 17.2.2. Israel 17.2.3. South Africa 17.2.4. Rest of MEA 17.3. Market Size (USD Million) Forecast for MEA 2022-2028 18. Market Share Analysis and Competitive Landscape 18.1. Global Landscape - Key Players, Revenue and Presence 18.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 18.3. Global Emerging Companies 18.4. North America - Market Share Analysis and Key Regional Players 18.5. Europe - Market Share Analysis and Key Regional Players 18.6. Asia Pacific - Market Share Analysis and Key Regional Players 18.7. Global Key Player - Growth Matrix 19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 19.1. Novartis AG 19.1.1. Company Overview 19.1.2. Product Portfolio 19.1.3. SWOT Analysis 19.1.4. Financial Overview 19.1.5. Strategic Overview 19.2.Bristol-Myers Squibb Company 19.2.1. Company Overview 19.2.2. Product Portfolio 19.2.3. SWOT Analysis 19.2.4. Financial Overview 19.2.5. Strategic Overview 19.3. Johnson & Johnson 19.3.1. Company Overview 19.3.2. Product Portfolio 19.3.3. SWOT Analysis 19.3.4. Financial Overview 19.3.5. Strategic Overview 19.4. Merck & Co. Inc. 19.4.1. Company Overview 19.4.2. Product Portfolio 19.4.3. SWOT Analysis 19.4.4. Financial Overview 19.4.5. Strategic Overview 19.5. Amgen Inc. 19.5.1. Company Overview 19.5.2. Product Portfolio 19.5.3. SWOT Analysis 19.5.4. Financial Overview 19.5.5. Strategic Overview 19.6. AbbVie Inc. 19.6.1. Company Overview 19.6.2. Product Portfolio 19.6.3. SWOT Analysis 19.6.4. Financial Overview 19.6.5. Strategic Overview 19.7. Eli Lilly and Company, 19.7.1. Company Overview 19.7.2. Product Portfolio 19.7.3. SWOT Analysis 19.7.4. Financial Overview 19.7.5. Strategic Overview 19.8. Galderma S.A. 19.8.1. Company Overview 19.8.2. Product Portfolio 19.8.3. SWOT Analysis 19.8.4. Financial Overview 19.8.5. Strategic Overview 19.9. GlaxoSmithKline plc 19.9.1. Company Overview 19.9.2. Product Portfolio 19.9.3. SWOT Analysis 19.9.4. Financial Overview 19.9.5. Strategic Overview 19.10.Mylan N.V. 19.10.1. Company Overview 19.10.2. Product Portfolio 19.10.3. SWOT Analysis 19.10.4. Financial Overview 19.10.5. Strategic Overview 19.11.LEO Pharma A/S. 19.11.1. Company Overview 19.11.2. Product Portfolio 19.11.3. SWOT Analysis 19.11.4. Financial Overview 19.11.5. Strategic Overview 19.12.Sanofi 19.12.1. Company Overview 19.12.2. Product Portfolio 19.12.3. SWOT Analysis 19.12.4. Financial Overview 19.12.5. Strategic Overview 19.13.Ortho-Clinical 19.13.1. Company Overview 19.13.2. Product Portfolio 19.13.3. SWOT Analysis 19.13.4. Financial Overview 19.13.5. Strategic Overview 19.14.Helena Laboratories 19.14.1. Company Overview 19.14.2. Product Portfolio 19.14.3. SWOT Analysis 19.14.4. Financial Overview 19.14.5. Strategic Overview 19.15.Sklar Surgical Instruments 19.15.1. Company Overview 19.15.2. Product Portfolio 19.15.3. SWOT Analysis 19.15.4. Financial Overview 19.15.5. Strategic Overview 20. Pre and Post COVID-19 Impact 20.1. Positive influence on the healthcare industry 20.2. The financial disruption of the manufacturing sector 20.3. Impact of COVID-19 on emerging companies 20.4. Significant mandates in the healthcare regulations initiated by administrations 20.5. The overall economic slowdown of the developing and developed nations 21. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Dermatology Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Dermatology Drugs Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Dermatology Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Dermatology Drugs Market, By Treatment Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Topical corticosteroids 7.2. Retinoids 7.3. Biologics 7.4. Calcineurin Inhibitors 7.5. Antihistamines 7.6. Hormone Therapy 7.7. Others
8. Dermatology Drugs Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Humira 8.2. Remicade 8.3. Otezla 8.4. Stelara 8.5. Enbrel 8.6. Cosentyx 8.7. Neoral 8.8. Taltz 8.9. Cubicin 8.10.Canesten 8.11.Zyvox 8.12.Dupixent 8.13.Protopic 8.14.Valtrex 8.15.Eucrisa 8.16.Others
9. Dermatology Drugs Market, By Prescription Mode Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Prescription drugs 9.2. OTC drugs
10. Dermatology Drugs Market, By Therapeutic Area Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Psoriasis 10.2. Atopic dermatitis 10.3. Acne 10.4. Rosacea 10.5. Skin Cancer 10.6. Scar 10.7. Others 11. Dermatology Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Direct 11.2. Wholesale/retail 11.3. Online
12. Dermatology Drugs Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 12.1. Hospital 12.2. Cosmetic Centers 12.3. Clinics
13. North America Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. U.S.A 13.2.2. Canada 13.2.3. Mexico 13.3. Market Size (USD Million) Forecast for North America 2022-2028
14. Latin America Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Brazil 14.2.2. Venezuela 14.2.3. Argentina 14.2.4. Rest of Latin America 14.3. Market Size (USD Million) Forecast for Latin America 2022-2028
15. Europe Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Germany 15.2.2. U.K 15.2.3. France 15.2.4. Italy 15.2.5. Spain 15.2.6. Russia 15.2.7. Poland 15.2.8. Rest of Europe 15.3. Market Size (USD Million) Forecast for Europe 2022-2028
16. Asia Pacific Dermatology Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. Japan 16.2.2. China 16.2.3. India 16.2.4. Australia and New Zealand 16.2.5. ASEAN 16.2.6. Rest of Asia Pacific 16.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
17. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 17.1. Introduction 17.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 17.2.1. GCC 17.2.2. Israel 17.2.3. South Africa 17.2.4. Rest of MEA 17.3. Market Size (USD Million) Forecast for MEA 2022-2028
18. Market Share Analysis and Competitive Landscape 18.1. Global Landscape - Key Players, Revenue and Presence 18.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 18.3. Global Emerging Companies 18.4. North America - Market Share Analysis and Key Regional Players 18.5. Europe - Market Share Analysis and Key Regional Players 18.6. Asia Pacific - Market Share Analysis and Key Regional Players 18.7. Global Key Player - Growth Matrix
19. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 19.1. Novartis AG 19.1.1. Company Overview 19.1.2. Product Portfolio 19.1.3. SWOT Analysis 19.1.4. Financial Overview 19.1.5. Strategic Overview 19.2.Bristol-Myers Squibb Company 19.2.1. Company Overview 19.2.2. Product Portfolio 19.2.3. SWOT Analysis 19.2.4. Financial Overview 19.2.5. Strategic Overview 19.3. Johnson & Johnson 19.3.1. Company Overview 19.3.2. Product Portfolio 19.3.3. SWOT Analysis 19.3.4. Financial Overview 19.3.5. Strategic Overview 19.4. Merck & Co. Inc. 19.4.1. Company Overview 19.4.2. Product Portfolio 19.4.3. SWOT Analysis 19.4.4. Financial Overview 19.4.5. Strategic Overview 19.5. Amgen Inc. 19.5.1. Company Overview 19.5.2. Product Portfolio 19.5.3. SWOT Analysis 19.5.4. Financial Overview 19.5.5. Strategic Overview 19.6. AbbVie Inc. 19.6.1. Company Overview 19.6.2. Product Portfolio 19.6.3. SWOT Analysis 19.6.4. Financial Overview 19.6.5. Strategic Overview 19.7. Eli Lilly and Company, 19.7.1. Company Overview 19.7.2. Product Portfolio 19.7.3. SWOT Analysis 19.7.4. Financial Overview 19.7.5. Strategic Overview 19.8. Galderma S.A. 19.8.1. Company Overview 19.8.2. Product Portfolio 19.8.3. SWOT Analysis 19.8.4. Financial Overview 19.8.5. Strategic Overview 19.9. GlaxoSmithKline plc 19.9.1. Company Overview 19.9.2. Product Portfolio 19.9.3. SWOT Analysis 19.9.4. Financial Overview 19.9.5. Strategic Overview 19.10.Mylan N.V. 19.10.1. Company Overview 19.10.2. Product Portfolio 19.10.3. SWOT Analysis 19.10.4. Financial Overview 19.10.5. Strategic Overview 19.11.LEO Pharma A/S. 19.11.1. Company Overview 19.11.2. Product Portfolio 19.11.3. SWOT Analysis 19.11.4. Financial Overview 19.11.5. Strategic Overview 19.12.Sanofi 19.12.1. Company Overview 19.12.2. Product Portfolio 19.12.3. SWOT Analysis 19.12.4. Financial Overview 19.12.5. Strategic Overview 19.13.Ortho-Clinical 19.13.1. Company Overview 19.13.2. Product Portfolio 19.13.3. SWOT Analysis 19.13.4. Financial Overview 19.13.5. Strategic Overview 19.14.Helena Laboratories 19.14.1. Company Overview 19.14.2. Product Portfolio 19.14.3. SWOT Analysis 19.14.4. Financial Overview 19.14.5. Strategic Overview 19.15.Sklar Surgical Instruments 19.15.1. Company Overview 19.15.2. Product Portfolio 19.15.3. SWOT Analysis 19.15.4. Financial Overview 19.15.5. Strategic Overview
20. Pre and Post COVID-19 Impact 20.1. Positive influence on the healthcare industry 20.2. The financial disruption of the manufacturing sector 20.3. Impact of COVID-19 on emerging companies 20.4. Significant mandates in the healthcare regulations initiated by administrations 20.5. The overall economic slowdown of the developing and developed nations
21. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics